Fasenra (benralizumab) belongs to a class of drugs known as monoclonal antibodies. It works by reducing the number of eosinophils cells.
Eosinophilic cells are vital white blood cells that help fight off infections and parasites, however, research suggests that eosinophils may cause the inflammation and airway obstruction seen in eosinophilic asthma.
By targeting and removing eosinophilic cells, Fasenra may help prevent airway blockages, asthma attacks, wheezing and shortness of breath, while improving lung function, and allowing for reduced daily steroid use.
Click here for additional side effects
Fasenra is given as a subcutaneous injection just under the skin
Given on day 1, week 4, week 8 and then every 8 weeks
Before your injection, it is important to drink plenty of water and come to your appointment hydrated. Additionally, you must alert us as soon as possible to any changes in your insurance to ensure that we are still an in-network provider for your infusion therapy.